Find a clinical trial

FindClinicalTrial

If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 12345 Next »
Viewing Page 1 of 21 | Showing Results 1 - 5 of 105

Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients with Metastatic Renal Cancer

This is a randomized, phase II study of IL-2 and SBRT in patients with metastatic renal cancer. Key Eligibility: * Histological confirmation of...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).

This is a multicenter, randomized, open-label, Phase 3 study to compare the efficacy and safety of lenvatinib in combination with everolimus (Arm...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma

The purpose of this study is to determine the efficacy and safety of nivolumab versus placebo in participants who have undergone radical surgery...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside
  • Oncology and Hematology Care Westside

A Pilot Study of DPV-001 DRibble Vaccine with Imiquimod in Advanced Prostate Cancer

This is a phase II trial of allogeneic DRibble vaccine, DPV-001, CTX and imiquimod to treat castrate resistant prostate cancer that has failed...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside

A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

The purpose of this study is to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside
« Previous 12345 Next »
Viewing Page 1 of 21 | Showing Results 1 - 5 of 105